Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies, Group Inc. is a pioneer in the research and development and marketing of medical nutritional supplements. Millennium owns the exclusive rights to RESURGEX® and RESURGEX Plusä, multiple action nutritional formulas containing the critically important, orally effective form of (SOD)/Gliadin (Defenzyme)) and several other essential nutritional components. Millennium products are designed to assist in increasing energy, maintaining lean muscle, reducing oxidative stress and supporting immune function in patients with HIV/AIDS, Hepatitis C, cancer or other immuno-compromised conditions as an adjunct to their medical care.
http://www.syntheticgenomics.com
Synthetic Genomics, Inc., a privately held company founded in 2005, is dedicated to developing and commercializing genomic-driven solutions to address global energy and environmental challenges. The scientific strength at Synthetic Genomics lies in the decades of pioneering scientific research by J. Craig Venter, Ph.D. and Nobel Laureate Hamilton O. Smith, M.D. The company's scientific team includes leading researchers with expertise in areas such as metabolic engineering, microbiology, biochemistry, bioinformatics, plant genomics, climate change and energy policies. In addition to the in-house research at Synthetic Genomics, the company is also funding synthetic genomic research at the J. Craig Venter Institute, a not-for-profit research organization with more than 400 staff and scientists dedicated to the advancement of the science of genomics, understanding its implications for society, and communicating those results to the scienfitic community, the public and policymakers.
Protana Inc., successor to the business of MDS Proteomics Inc., offers an integrated suite of leading-edge technologies - protein identification, protein interaction mapping, differential analysis, phosphoprofiling, chemical proteomics, bioinformatics, small molecule hit discovery and lead optimization- that can be applied across the entire drug discovery and development process. Protana's combination of world-class experts and sophisticated technology is committed to providing the global medical community and biopharmaceutical industry with leading-edge solutions for the diagnosis and treatment of disease. Protana is one of the world's leading experts in the mass spectrometry analysis of proteins. The company has published studies in Nature, Nature Biotechnology, and Proceedings of the National Academy of Sciences. Protana Inc. has been recognized as a Technology Pioneer by the World Economic Forum and was the recipient of the prestigious 2005 Frost and Sullivan Growth Strategy Leadership Award. The information on this and/or any other page on this website is subject to change without notice. Any use of this website is subject to the policies, disclaimers, and conditions set by Protana Inc. Please read our terms of use and legal notice.
Mirus Bio Corporation is a biopharmaceutical company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products. Under development are RNAi gene silencing therapies based on Mirus' proprietary Dynamic PolyConjugatesÔ delivery platform and gene therapies utilizing its Pathway IVÔ delivery protocol. Commercially, Mirus markets a range of innovative transfection and labeling research reagents worldwide. Dynamic PolyConjugates ("DPC") is a targeted systemic siRNA delivery platform. Our proprietary polymer based formulation chemistry efficiently targets gene silencing complexes to specific cells. As the DPCs attach to and enter the target cells, they respond to the environmental cues provided by the cell to disassemble and release the active siRNA molecule. This unique chemistry mimics the natural viral targeting and disassembly process. This technology is currently being optimized for liver and cancer tissues, and is actively being evaluated by select partners for research and clinical indications. Pathway IV is a clinically practical procedure based upon intravenous ("IV") delivery of plasmid DNA ("pDNA") to targeted limb muscle. With blood flow temporarily occluded by a tourniquet, a DNA solution is rapidly injected into a suitable vein. This elevates the pressure within the occlusion zone, making the blood vessel wall more permeable and allowing the pDNA to migrate into the adjoining muscle cells. Blood flow is then restored to normal within a few minutes, with only mild transient affects to the vasculature. This quick, robust procedure is being used as an enabling platform that will provide first-in-class therapeutic treatments for muscular dystrophy, peripheral ischemia and other diseases. Patients with the most common muscular dystrophies, Duchenne and Becker, suffer from a genetic defect in which dystrophin protein is either poor or inadequate in their muscle cells. It affects roughly 1 of every 3500 male births. MyoDys® will treat this disease by inserting a gene encoding active dystrophin into affected muscles to delay or prevent loss of muscle function. Peripheral ischemia is a condition in which reduced blood supply to limbs causes claudication (cramping), chronic pain, and potentially loss of the limb. It is common in diabetics and the elderly, where up to 20% of those over age 70 experience intermittent claudication. Mirus' treatment is based upon delivery of a gene encoding an angiogenic factor to the affected limb, which induces revascularization of the limb. In the future, the company envisions using muscle as the host site for gene therapies that induce secretion of therapeutic proteins to treat a range of diseases, including anemia, arthritis, ALS, and cancer immunotherapeutics. Mirus R&D uniquely integrates nucleic acid delivery and chemistry, a core competency which is unmatched in the industry. This serves as the foundation for both its novel research reagents and emerging therapeutics. The company maintains advanced research programs focused on synthetic siRNA delivery, and on gene delivery to liver and other target tissues. Access to Mirus' technologies is available through strategic alliances as well as licensing in nonstrategic fields. Mirus is well positioned to be a partner of choice due to its consistent record of profitability; driven by the sales growth of its research reagents.
Microbix Biosystems Inc. is a Canada-based company. The Company is engaged in the development, manufacturing and distribution of cell-based products and technology and, provision of facility, technical and production personnel for contract research and development. Sequent Biotechnologies Inc. is the Company’s wholly owned subsidiary. In September 2008, the Company announced that it has divested its urokinase business to Microbix Biosystems Inc. Through this transaction, Microbix has acquired the remaining urokinase inventory and related assets and has assumed full responsibility for ongoing commercial and regulatory activities associated with the product. Urokinase is an United States Food and Drug association (FDA)-approved thrombolytic, or clot-dissolving agent, indicated for the treatment of acute massive pulmonary embolism.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory